Radio-induced lymphopenia in the era of anti-cancer immunotherapy.

3区生物学 Q1 Biochemistry, Genetics and Molecular Biology

International review of cell and molecular biology Pub Date : 2023-01-01 DOI:10.1016/bs.ircmb.2023.03.002

François de Kermenguy, Lydia Meziani, Michele Mondini, Céline Clémenson, Daphné Morel, Eric Deutsch, Charlotte Robert

{"title":"Radio-induced lymphopenia in the era of anti-cancer immunotherapy.","authors":"François de Kermenguy, Lydia Meziani, Michele Mondini, Céline Clémenson, Daphné Morel, Eric Deutsch, Charlotte Robert","doi":"10.1016/bs.ircmb.2023.03.002","DOIUrl":null,"url":null,"abstract":"<p><p>Radiation-induced lymphopenia (RIL) is characterized by a significant decrease in the absolute number of lymphocytes circulating in the blood after radiotherapy. With the major shift in cancer management initiated by cancer immunotherapy (IT), the reduction of incidence of RIL appears today as an extremely promising way of potentiating the synergy between radiotherapy and immunotherapy. However, the causes of RIL and mechanisms involved are still poorly understood. Improving our knowledge on RIL is therefore essential to limit it and thus improve the quality of care delivered to patients. The objective of this review is to provide a global view of RIL from a clinical point of view, with particular emphasis on recent knowledge and avenues explored to explain RIL and especially its depletion and remission kinetics. An opening on treatment concepts to be rethought is conducted in the context of combined RT/IT treatments.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"378 ","pages":"1-30"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International review of cell and molecular biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/bs.ircmb.2023.03.002","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 1

Abstract

Radiation-induced lymphopenia (RIL) is characterized by a significant decrease in the absolute number of lymphocytes circulating in the blood after radiotherapy. With the major shift in cancer management initiated by cancer immunotherapy (IT), the reduction of incidence of RIL appears today as an extremely promising way of potentiating the synergy between radiotherapy and immunotherapy. However, the causes of RIL and mechanisms involved are still poorly understood. Improving our knowledge on RIL is therefore essential to limit it and thus improve the quality of care delivered to patients. The objective of this review is to provide a global view of RIL from a clinical point of view, with particular emphasis on recent knowledge and avenues explored to explain RIL and especially its depletion and remission kinetics. An opening on treatment concepts to be rethought is conducted in the context of combined RT/IT treatments.

查看原文本刊更多论文

抗癌免疫治疗时代的放射性淋巴细胞减少症。

放射诱导淋巴细胞减少症(RIL)的特点是放射治疗后血液中循环淋巴细胞的绝对数量显著减少。随着癌症免疫治疗(IT)引发的癌症管理的重大转变，降低RIL的发生率今天似乎是加强放射治疗和免疫治疗之间协同作用的极有希望的方法。然而，RIL的病因和相关机制仍然知之甚少。因此，提高我们对RIL的认识对于限制它，从而提高向患者提供的护理质量至关重要。本综述的目的是从临床角度提供RIL的整体观点，特别强调最近的知识和途径，以解释RIL，特别是其消耗和缓解动力学。在RT/IT联合治疗的背景下，对治疗概念进行了重新思考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International review of cell and molecular biology BIOCHEMISTRY & MOLECULAR BIOLOGY-CELL BIOLOGY

CiteScore

7.70

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： International Review of Cell and Molecular Biology presents current advances and comprehensive reviews in cell biology-both plant and animal. Articles address structure and control of gene expression, nucleocytoplasmic interactions, control of cell development and differentiation, and cell transformation and growth. Authored by some of the foremost scientists in the field, each volume provides up-to-date information and directions for future research.